A 42-year-old woman with a 2-month history of progressive dyspnea, hemoptysis, and sinusitis presents with a serum creatinine of 2.8 mg/dL (baseline 0.9 mg/dL) and active urinary sediment (RBC casts, proteinuria 2.5 g/day). Chest X-ray shows bilateral pulmonary infiltrates. ANCA testing is pending. What is the most appropriate immediate next step in management?

Question

Accepted Answer

C. Start intravenous methylprednisolone 1 g daily × 3 days and intravenous cyclophosphamide 0.5–1 g/m² immediately. ## Clinical Scenario Analysis

This patient has **ANCA-associated vasculitis (AAV)** with **rapidly progressive glomerulonephritis (RPGN)** and **pulmonary involvement** — a medical emergency.

### Key Clinical Features
- Triad of upper respiratory (sinusitis), lower respiratory (hemoptysis, infiltrates), and renal involvement (RBC casts, rising creatinine)
- Rapid decline in renal function (creatinine 0.9 → 2.8 mg/dL in 2 months)
- Active urinary sediment with RBC casts (hallmark of RPGN)
- Proteinuria 2.5 g/day
- Bilateral pulmonary infiltrates

**Key Point:** This clinical triad strongly suggests **granulomatosis with polyangiitis (GPA, formerly Wegener granulomatosis)**, though microscopic polyangiitis (MPA) or eosinophilic granulomatosis with polyangiitis (EGPA) are in the differential. The presence of upper respiratory involvement favors GPA.

### Why Immediate Aggressive Immunosuppression?

**High-Yield:** RPGN in AAV is a **medical emergency**. Untreated, it progresses to **end-stage renal disease (ESRD)** within weeks to months. Every day of delay increases the risk of irreversible renal failure. Treatment must be initiated **immediately** — even before ANCA confirmation — if clinical suspicion is high.

**Mnemonic: RPGN = RAPID RENAL RESCUE**
- R = Rapidly progressive glomerulonephritis
- P = Pulmonary hemorrhage (hemoptysis)
- G = Granulomatosis (GPA)
- N = Needs immediate aggressive therapy

### Management Algorithm for ANCA-Associated Vasculitis with RPGN

```mermaid
flowchart TD
  A["Suspected AAV with RPGN"]:::outcome --> B{"Severe renal involvement?"}:::decision
  B -->|"Creatinine >2.5 mg/dL or dialysis-dependent"| C["IV methylprednisolone 1 g daily × 3–5 days"]:::urgent
  C --> D["IV cyclophosphamide 0.5–1 g/m² (or rituximab 375 mg/m² weekly × 4)"]:::urgent
  D --> E["Transition to oral prednisolone 1 mg/kg/day"]:::action
  E --> F["Continue cyclophosphamide or switch to azathioprine/MMF for maintenance"]:::action
  B -->|"Creatinine <2.5 mg/dL, mild renal disease"| G["Oral prednisolone + azathioprine or rituximab"]:::action
  F --> H["Monitor renal function, ANCA titers, inflammatory markers"]:::action
  G --> H
```

### Induction Therapy Regimens for Severe AAV

| Feature | IV Methylprednisolone | Oral Prednisolone |
|---------|----------------------|-------------------|
| **Indication** | Severe renal/pulmonary disease | Mild-moderate disease |
| **Dose** | 1 g daily × 3–5 days | 1 mg/kg/day (max 80 mg) |
| **Advantage** | Faster onset, higher intraocular/renal concentration | Convenient, oral route |
| **Transition** | Switch to oral prednisolone after IV phase | Maintenance dose |

### Cyclophosphamide vs. Rituximab

| Agent | Cyclophosphamide | Rituximab |
|-------|------------------|----------|
| **Dose** | 0.5–1 g/m² IV monthly × 6 months | 375 mg/m² weekly × 4 weeks |
| **Indication** | Severe renal/pulmonary disease; preferred if dialysis-dependent | Alternative to cyclophosphamide; emerging first-line |
| **Advantage** | Proven efficacy in RPGN; rapid response | Fewer infections, no hemorrhagic cystitis |
| **Toxicity** | Hemorrhagic cystitis, infertility, infection, malignancy | Infusion reactions, hypogammaglobulinemia |
| **Maintenance** | Switch to azathioprine or MMF after induction | Rituximab maintenance or switch to azathioprine |

**Clinical Pearl:** The ANCA type (c-ANCA/PR3 in GPA vs. p-ANCA/MPO in MPA) does not change acute management. Both require immediate aggressive immunosuppression if RPGN is present.

### Why Correct Answer is Right

**IV methylprednisolone 1 g daily × 3 days + IV cyclophosphamide 0.5–1 g/m²** is correct because:

1. **Severe renal disease**: Creatinine 2.8 mg/dL with RBC casts indicates RPGN requiring aggressive induction.
2. **Pulmonary involvement**: Hemoptysis + infiltrates suggest pulmonary vasculitis, which also warrants IV therapy.
3. **Standard of care**: EULAR/ERA-EDTA and ACR guidelines recommend IV methylprednisolone + cyclophosphamide (or rituximab) for severe AAV with RPGN.
4. **Time-sensitive**: Delaying treatment risks irreversible renal failure and death from pulmonary hemorrhage.
5. **ANCA not required**: Clinical diagnosis (triad + RPGN + elevated inflammatory markers) is sufficient to initiate therapy; ANCA results confirm but do not delay treatment.

**High-Yield:** After IV induction (methylprednisolone × 3–5 days + cyclophosphamide × 6 months), transition to **maintenance therapy** with azathioprine 2 mg/kg/day or mycophenolate mofetil 2–3 g/day for 12–24 months to prevent relapse.

Answer

A. Obtain high-resolution CT chest and defer immunosuppression until ANCA results return

Answer

B. Initiate oral prednisolone 1 mg/kg/day and azathioprine; repeat ANCA in 2 weeks

Answer

D. Perform renal biopsy to confirm ANCA-associated vasculitis before starting immunosuppression

Explanation

Practice similar questions